Kumaraguru Raja
Stock Analyst at Brookline Capital
(n/a)
# 4,812
Out of 4,814 analysts
15
Total ratings
8.33%
Success rate
-58.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.00 | +799.82% | 1 | Dec 18, 2024 | |
| PALI Palisade Bio | Initiates: Buy | $38 | $0.72 | +5,185.12% | 1 | Nov 20, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $1.44 | +457.49% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $6.82 | +1,366.28% | 2 | May 30, 2024 | |
| HEPA Hepion Pharmaceuticals | Downgrades: Hold | n/a | $0.32 | - | 1 | Dec 7, 2023 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $1.45 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.73 | +20,447.95% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $3.69 | +306.50% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $2.79 | +654.04% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $40.12 | +124.33% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $31 | $0.53 | +5,799.14% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,360 | $0.71 | +473,139.44% | 1 | Sep 21, 2021 |
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.00
Upside: +799.82%
Palisade Bio
Nov 20, 2024
Initiates: Buy
Price Target: $38
Current: $0.72
Upside: +5,185.12%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $1.44
Upside: +457.49%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $6.82
Upside: +1,366.28%
Hepion Pharmaceuticals
Dec 7, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.32
Upside: -
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.45
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.73
Upside: +20,447.95%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $3.69
Upside: +306.50%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $2.79
Upside: +654.04%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $40.12
Upside: +124.33%
May 18, 2022
Maintains: Buy
Price Target: $29 → $31
Current: $0.53
Upside: +5,799.14%
Sep 21, 2021
Initiates: Buy
Price Target: $3,360
Current: $0.71
Upside: +473,139.44%